Moderna’s spending cuts, pipeline shakeup leave doubts about a rebound, analysts say

Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of downgrades as analysts focused on longer timelines to launch some products and questioned when the company can return to profitability.